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a b s t r a c t 
Background: There has been a lack of in-depth interviews investigating patient experience of ketamine treatment 
for depression. We examined participants’ pathways to receiving ketamine infusion to treat their depression, and 
their responses to, lived experiences of, and attitudes towards ketamine treatment. 
Methods: Qualitative methods were used to conduct in-depth interviews with 13 patients (6 male; 7 female) diag- 
nosed with treatment resistant depression (TRD) with experience of receiving ketamine treatment for depression. 
Interpretative phenomenological analysis (IPA) was employed. 
Results: For the majority of participants ketamine infusion causes a reported initial ‘high’, enhanced perception, 
and dissociative experience; followed by a lifting of mood and a reduction in or removal of suicidal ideation and 
depression symptoms lasting around 3–6 days. This leads to a reported increase in motivation, socialisation, and 
activity. All participants valued the therapeutic alliance with clinicians which enhanced the treatment experience 
and all advocated treatment access for those with depression who have not responded to other treatments. 
Limitations: Small numbers, purposive sample, participant self-selection, and single site recruitment limit gener- 
alisability. 
Conclusions: Ketamine for depression can have many beneficial effects, and it is potentially life-transforming for 
some. Ketamine may be a source of hope for patients for whom other treatments have not been effective. For 
some, ketamine is not tolerated or does not have anti-depressive effects. Further qualitative in-depth exploration 
of patient experience and consideration of how ketamine depression treatment access can be appropriately made 




































Some people diagnosed with major depressive disorder (MDD)
re poor or non-responders to widely used antidepressant medica-
ion, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-
orepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants
TCAs) and monoamine oxidase inhibitors (MAOIs) ( Henkel et al.,
009 ). These drugs are often not fast-acting, having a typical time lag
f 2–4 weeks initially, and 6–12 weeks for maximum effect ( Niciu et al.,
015 ). Over 50% of people do not experience remission after first-line
ntidepressant medication, and one-third do not after four different
ourses ( Rush et al., 2006 ); and many experience negative side effects
 Anderson et al., 2012 ). Non-response rate to psychotherapy (typically
ognitive behavioural therapy [CBT]), has been reported at around 62–
0% ( Gyani et al., 2013 ; Griffiths and Griffiths, 2015 ). ∗ Corresponding author. 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) Treatment resistant depression (TRD) may be defined as no re-
ponse to at least two consecutive courses of antidepressant medication
 Berlim and Turecki, 2007 ). Between 12% and 30% of depressed pa-
ients have TRD ( Rush et al., 2006 ; Nemeroff, 2007 ; Eaton et al., 2008 ;).
RD is associated with higher rates of psychosocial dysfunction, morbid-
ty, mortality, suicide, and health service costs ( McCrone et al., 2008 ;
iciu et al., 2015 ; Balestri et al., 2016 ). Effective treatment options for
RD include: electroconvulsive therapy (ECT) (reported remission rates
f around 50% ( Jevolac et al., 2013 ); side effects include short and
ong term memory loss ( Mohn and Rund, 2016 ; Griffiths and O’Neill-
err, 2019 )) and transcranial magnetic stimulation (TMS) (reported re-
ission rates of 21–50%) ( Griffiths et al., 2019 ). Some people do not re-
pond to, are excluded from (due to e.g. metal head implants, epilepsy),
r prefer not to try either ECT or TMS. 
Ketamine (N-methyl-D-aspartate receptor antagonist) is a rapid-
cting antidepressant ( Fond et al., 2014 ; Coyle and Laws, 2015 ; January 2021 
ticle under the CC BY-NC-ND license 



















































































































ishimoto et al., 2016 ; Grady et al., 2017 ) and may decrease suici-
al ideation ( Canuso et al., 2018 ; Lascelles et al., 2019 ). Ketamine has
aximal antidepressant effects at 24 hours which abates within 7 days
varies between individuals) ( Phillips et al., 2019 ). Examining 10 sys-
ematic reviews, Lent et al. (2019) concluded ketamine significantly
educes depression severity in the short term. Adverse effects include
sychotic and dissociative effects, blood pressure and heart rate fluctua-
ions, blurred vision and drowsiness ( Grady et al., 2017 ). Although there
s a lack of evidence examining the longer-term effects, repeated weekly
etamine infusions may have cumulative and sustained antidepressant
ffects ( Phillips et al., 2019 ). Increasingly, ketamine is prescribed for
eople with TRD ( Krystal et al., 2019 ). 
Qualitative research investigating patient experience of ketamine is
acking. Using focus group and survey data, Jilka et al. (2019) consid-
red carers’ and patients’ attitudes towards and experience of ketamine.
articipants thought ketamine was an effective antidepressant, wanted
etter long-term evidence (effect, safety and side effects), stated prac-
ical issues of accessing treatment were important (cost, travel for in-
usions), and felt clinicians need to know about ketamine treatment.
owever, only a minority (39%) of participants had experience of ke-
amine for depression and their opinions were not consistently sepa-
ately reported. Van Schalkwyk et al. (2018) interviewed 10 participants
ho had received ketamine for depression, and reported four promi-
ent themes: unusual bodily sensations, a sense of peace, disinhibition,
nd a sense of altered perception. Finally, interviewing 14 depressed
atients with suicidal ideation, Lascelles et al. (2019) found following
etamine, they reported reduced suicidal ideation, associated with im-
roved mood, clarity of thought, focus, concentration, and ability to
unction, and reduced anxiety; and indicated further studies of patients’
xperiences are warranted. The aim of this current paper is to exam-
ne participants’ pathways to trying, lived experiences of and responses




A qualitative design was employed using semi-structured interviews.
nterpretative phenomenological analysis (IPA) allowed: exploration of
ow participants made sense of their lives; nuanced analysis of particu-
ar instances and experiential phenomenon; and an examination of the
eaning of experiences, events, states and contexts held for each par-
icipant ( Smith and Osborn, 2003 ; Smith et al., 2012 ). 
.2. Recruitment 
Ethical approval gained from UK Health Department’s Health Re-
earch Authority (HRA) (project ID: 2707478). The sample was recruited
urposefully from those who have received ketamine infusion treatment
ithin an NHS trust. Participants were included if they were aged 18 or
ver, had experienced ketamine depression treatment (at least 3 ses-
ions), had the capacity to consent, and the ability to understand En-
lish. 
.3. Procedure 
Two of the interviews took place face-to-face at the treatment centre.
he rest were carried out over the phone, participants taking the calls
t home. Areas covered in the interview schedule: (i) decisions around
sing ketamine; (ii) experience of ketamine during and following treat-
ent; (iii) effects of ketamine treatment; (iv) impact ketamine treatment
ad on life, mood, cognition, wellbeing, motivation, social life, sleep;
v) changes experienced through ketamine treatment; (vi) feedback on
ervice provision; (vii) any other comments. 2 Thirteen interviews were conducted. In eleven just the patient and
he interviewer were present; for two of the interviews, the patients’
artners were present and participated in the interview process, as
he patients requested guidance from partners to prompt and assist
ith memory issues. Interview length ranged from 16 to 62 minutes
 M = 43.53 , SD = 13.24). All interviews were digitally recorded and
ully transcribed. 
.4. Analysis 
The analysis followed an iterative and inductive cycle strategy
 Smith, 2007 ). All transcripts were individually read and re-read, and
nitial codes were developed by two researchers. These codes were
hared with the third researcher, where emergent themes were struc-
ured, and provisional titles agreed upon. Charting and mapping themes
as undertaken where connections across emergent themes were iden-
ified and initial super-ordinate and associated themes were developed.
nce completed on an individual participant basis, patterns were iden-
ified through comparisons across the whole dataset. Following the syn-
hesising of the patterns and themes across all datasets, key themes were
efined and relabelled. The themes were grounded in the data, and con-
ensus of patterns across participants were identified and exceptions
oted. 
To ensure trustworthiness of the data, strategies were employed to
romote credibility, transferability, dependability and confirmability
f the research, as informed by Shenton (2004) . This comprised sev-
ral processes: (a) the utilisation of well-established research methods
n qualitative investigation; (b) frequent debriefing sessions; (c) use of
ransparent and in-depth protocol for data collection and analysis; (d)
eeping detailed logbook, memos, notes, and extensive records through-
ut the analytical process; (e) construction of a data orientated audit
rail; and (f) examination and verification by three researchers of anal-
sis undertaken and the conclusions drawn. 
. Results 
.1. Participants 
All 13 participants (6 male; 7 female) identified as ‘White British’.
he age range was 30.19–59.65 years ( M = 46.05, SD = 10.69). All par-
icipants had TRD, other recorded diagnoses included: bipolar affective
isorder ( n = 2), mixed anxiety depressive disorder ( n = 1), schizoaffec-
ive disorder ( n = 1). 
The number of ketamine sessions ranged from 3 to 112 ( M = 34.69,
D = 39.61). The individual dose of ketamine was calculated by factors
uch as height and weight. Doses given ranged from 25 mg/40 mls to
5 mg/40 mls, all infused over 40 min ( M = 48.61, SD = 14.52). There
ere no gender differences in doses; however, ketamine treatment ses-
ions were significantly higher for women ( U = 6, p = .035), 56.57 ses-
ions ( SD = 43.76) compared to 9.17 sessions in men (SD = 3.87). 
.2. Findings 
The themes identified are in Table 1 . They correspond to a chrono-
ogical flow through the treatment pathway, from the decision-making
rocesses pre-treatment, to experience of ketamine treatment, the en-
ancers of or barriers to treatment, and participants’ advocacy of treat-
ent. 
.3. Treatment decision influences 
This theme represents how and why patients decided to try ketamine.
he decision-making processes are divided into three themes that cap-
ure participants’ thought processes, motivations and sources of knowl-
dge that influenced and led to their decision. 
C. Griffiths, K. Walker, I. Reid et al. Journal of Affective Disorders Reports 4 (2021) 100079 
Table 1 
Table of themes. 
Master Theme Themes Subthemes 
1. Treatment decision influencers 
⇒ Desperation 
⇒ Risk-rewards, pros-cons evaluation 
⇒ Trusted advice and 
recommendations 
2. Responses experienced taking 
ketamine 
⇒ Physiological ⇒ Dissociation, a high 
⇒ Relaxed and sleepy 
⇒ Heightened sensory perception 
⇒ Adverse side effects 
⇒ Emotional ⇒ Happy and laughing 
⇒ Uplifted feeling, brightened mood 
⇒ Feeling ‘normal’ and like ‘true self’ 
⇒ Behavioural ⇒ Actively undertake activities 
⇒ Sociable and communicative with 
others 
⇒ Cognitive ⇒ Positive thoughts increased, 
negative thoughts decreased 
⇒ Reduced suicidal ideation 
⇒ Reframing thoughts and 
reprogramming mindset 
⇒ Motivated thinking and a want to 
take action 
⇒ Life-changing, a profound impact 
3.Treatment enhancers 
⇒ Conducive and safe environment 
⇒ Medical expertise and 
professionalism 
⇒ Therapeutic alliance with caring 
staff
4. Barriers to treatment efficacy and 
success 
⇒ Being a non-responder to 
ketamine 
⇒ Loss of ketamine effects over time 
⇒ Negative external & environmental 
factors 
























Being desperate for ‘something’ that would help their depression was
pparent across all narratives. Seven participants used the word ‘desper-
te’: ‘ desperate is a good summation’ (P10). Participants had tried many
reatment options without enduring success, and were experiencing pro-
onged, severe depression; they were seeking new forms of treatment: 
P9: in absolute honesty...I had reached a point where I was willing to try
almost anything to get my mental health back to a level where I felt I
could function as a human being again. 
Participants suggested this was a last resort for them; they had run
ut of options: 
P13: it was a last-ditch attempt at… jump-starting… any kind of recov-ery…I was getting desperate 
3 .3.2. Risks-rewards, pros-cons evaluation 
The majority of participants made an assessment of the
osts/risks/benefits of ketamine: 
P1: It was very well documented, on how it worked …it was very quick
acting…I don’t know about lasting too long, it very quickly had the
benefit that I wanted which was to feel better, yes and it just made
sense to just try it. 
Even following a negative reaction a participant felt the benefits out-
eighed the risks: 
P6: I’d try it again… am I nervous? ...Yes I am, totally, absolutely….
Would I have it done? Yes, because I, I know that the rewards out-
weigh the risk… I’ve had a turn; I’m prepared to take that risk, orcalculated risk, to have it done again. 






























































































.3.3. Trusted advice and recommendations 
Ketamine treatment was relatively unknown to the majority of par-
icipants prior to description by medical professionals. The participants
eported a good relationship and rapport with the psychiatrists and nurs-
ng staff, and as a result trusted their opinion and advice. This influenced
heir decision to try ketamine: 
P10: The fact that I really trusted [psychiatrist’s name]. Because he knew
me inside and out, he’s an expert in his field, I put myself in his hands
and I was willing to go with what he felt. 
.4. Responses experienced taking ketamine 
This theme is made up of five sub-themes, which collate the partic-
pants’ experiences of responses to ketamine, in the immediate, short
nd longer term. 
.4.1. Physiological 
This theme is divided into four subthemes, generally experienced
uring the infusion or shortly following. 
.4.1.1. Dissociation, a high. Participants revealed during infusions they
xperienced dissociation, or out of body experiences: ‘ So the dissociation
as, was definitely there’ (P13), and ‘ the dissociation, I feel that very much’
P10), others described how this felt: 
P12: it was almost like an out of body experience… I tried to lift up my
arm, it was almost like it wasn’t me, I was like watching my arm being
lifted up. 
For some there was a feeling of being high, a ‘ trippy experience ’ (P12);
ith several participants describing the physiological responses similar
o taking psychoactive drugs or alcohol: 
P4: You’ve got no controls, you know, everything seems a bit funny, it, it
makes you a bit high. 
P1: arms and legs feel quite heavy, you might start feeling a little giddy. 
.4.1.2. Relaxed and sleepy. Participants described a relaxed, sleepy,
oaty feeling that was pleasant in nature during the infusion: 
P1: kind of like just floaty, in and out state of kind of sleep. 
P3: well I used to nod off! 
.4.1.3. Heightened sensory perception. During the infusion and for a
hort period afterwards, participants described how they experienced
eightened senses and perceptions, particularly in relation to noise and
ision. Several participants described how colours were more vibrant
nd brighter: 
P12: Certain colours like I had never seen them as they were be-
fore…things like the colour red, so like brake lights and cars and just
things like that, that I had never seen a brake light as vibrant before.
Participants recalled how noises became ‘ like almost amplified’ (P12),
ividly recalling ‘ clippy-cloppy heels, banging of doors ’ (P3), ‘ birds tweeting’
P8), and ‘ lorries reversing’ (P6). 
.4.1.4. Adverse side effects. Some physiological responses were not
leasant experiences. These varied in type and severity, including nau-
ea, headaches, and adverse physiological reactions: 
P1: During the treatment…I would always have low blood pressure…so
a few times I had to be laid down flat very quickly. 
Some of the adverse effects included an outpouring of grief and cry-
ng, whilst another participant experienced panic: 
P12: It was almost like an impending doom, like I was panicking. 
For the majority these unpleasant experiences were manageable, and
hey were able to continue with treatment. However, for three of the
articipants the adverse side effects, such as horrific hallucinations or
xceptionally high temperature, meant that treatment was stopped. 4 .4.2. Emotional 
This theme is represented by three subthemes, which describe dif-
erent emotional responses during the infusion and following. 
.4.2.5. Happy and laughing. For many this feeling started during the
nfusion, where they talk about laughing. This was a therapeutic part of
he process making it an enjoyable experience: 
P1: I do think laughter is the best, best drug…..with the nurse tending me
today…I had tears of laughter and she did as we, we were laughing
so much. 
Happiness was something that some participants felt continued
hrough the following days. Several participants used the word
 happy/happier’ , in contrast to previously seeing themselves as unhappy:
P3: And Mum [P3] was happy! And Mum hadn’t been happy for many
years, and seriously not happy….they [family] were really pleased
because I was so happy. I mean I would bounce off the walls over the
weekend . 
.4.2.6. Uplifted feeling, brightened mood. Participants experienced an
verall lift in their mood: 
P2: It gives me space, so lifts me, my emotions, my feelings, my mind, my
spirit, my well-being. 
This lifted mood was something that was experienced during and af-
er the infusion, and for some was sustained over a few days or longer.
articipants described themselves as ‘ elated ’ (P2), that their ‘ mood is
ifted ’ (P8), they ‘ felt bright ’ (P7), and had ‘ fire in their belly ’ (P6). These
eelings were a stark comparison to feelings when depressed: 
P2: It just lifts darkness away. 
P3: It brightened my mood and it, it lightened it. Again, until the Tuesday,
and I’d start to slip down into depressive mode and suicidal mode and
have dark thoughts. 
.4.2.7. Feeling ‘normal’ and like ‘true self’. Participants explained how
hey felt normal, a person without symptoms of depression: 
P6: I felt normal. Or I seemed to feel like just a normal person, just func-
tioning. 
Ketamine enabled them to be their real and true self: 
P7: I just felt like myself again…I used to just, it was like putting a front
on for people just to be what they wanted me to be, not what I really
was. But after the ketamine, it was me, it was me. I really felt, it was
real. 
.4.3. Behavioural 
Participants described noticeable and concrete positive changes in
heir behaviours following ketamine, some maintained over longer pe-
iods of time. For example, improved night-time sleep: ‘instead of your
rain whirring away with stuff that does not matter, I’d go to bed… shut me
yes, my eyes would be open in the morning… I’d be ready to go again’ (P6).
his theme comprises two subthemes. 
.4.3.8. Actively undertake activities. Participants described how they
ere able to undertake activities such as: cooking, showering, visiting
riends, cleaning the house, going to the gym, work, sport, and walking
he dog. Participants explained they had the motivation to undertake
hese activities and implement them: 
P3: I wanted to do things. I wanted to have a shower and doing my
housework, walking the dog, just normal things that everybody takes
for granted, I couldn’t do. But once I’d had a ketamine, I could do all
those things. 
























































































P10: I joined a running club 
P11: Guitar… I started having lessons again. Go to classes at the gym…
go running 
P7: I had an interview… I would never have… even thought about work…
it was successful… I have been working ever since. 
.4.3.9. Sociable and communicative with others. Participants found that
heir ability and desire to socialise and communicate improved greatly,
nd for some this lasted longer term. Individuals expressed: ‘ I was a lot
ore sociable’ (P8); for some this meant improved relationships: ‘ The
elationship we [with daughter] have got [now] is amazing, it’s lovely ’ (P7).
any identified this as a radical change: 
P3: I was quite happy to see people and entertain people and ask people
to come back to my home, which is unheard of. But again, since I’ve
been off the ketamine, I don’t, nobody comes into my home. 
.4.4. Cognitive 
This theme is about a change in cognitive focus: ‘ it just enables be to
hink ’ (P10), ‘ definitely concentrate more ’ (P11), ‘ I can rationalise’ (P7), ‘ I
as much sharper’ (P3), and shifts in thinking patterns and mindset. This
heme is made up of 4 subthemes. 
.4.4.10. Positive thoughts increased, negative thoughts decreased. The
articipants described a two-way process: negative thoughts diminished,
eplaced by positive thoughts: 
P1: I could see a future, I could see that I was capable of doing things…I
didn’t kind of feel the sort of the negative person sitting on your shoul-
der telling you that you can’t do this there’s a problem here…. It was
almost as if…the angel and the demon on your shoulder, and all you
could hear was the angel. 
There was a shift to less anxiety, looking forward to things, being
otivated and generally feeling good. 
.4.4.11. Reduced suicidal ideation. This radical change occurred for
round half of the participants: ‘ before the treatment I was really quite sui-
idal, that’s all but disappeared ’ (P1), ‘ I haven’t been suicidal for three years’
P2). The participants described how previous dark, suicidal thoughts
ere replaced with positive thoughts about improved self-worth, an
bility to see a future and a renewed desire to live: 
P10: My zest for life has returned, my outlook is back in terms of I have
an outlook, instead of thinking, I, you know there is no point and
optimism is gone. Like the thought of leaving life is, I just can’t com-
prehend that that was me who thought that . 
.4.4.12. Reframing thoughts and reprogramming mindset. Participants
xperienced a complete change in their mindset and the ability to re-
rame their thinking: 
P1: Almost as if it rewired the brain very quickly and it kind of just
matched things up the way they should be, rather than what they felt
they were. 
P2: It is the treatment that has… helped me to re-programme myself or
play a different record. You’d see the bigger picture… you realise that
there is more to life than worrying over stuff you cannot change. If
you can change it, brilliant, go ahead and change it. 
This encapsulated new positive, future-focused thinking experi-
nced: 
P10: I drive there [treatment centre] and everything is grey and black,and I come out and it is technicolour. It really is… that powerful. 
5 .4.4.13. Motivated thinking and a want to take action. Related to be-
avioural motivation and implementation of activities, this theme is dif-
erentiated as a cognitive response; participants talked about motivated
houghts and thinking without examples of implementation: 
P2: [after treatment] I’m still thinking I want to do something, I want to
be more active with my life, I want to get on with life. 
Participants expressed motivated thinking and a desire to do a range
f things including developing their career, going out to visit places,
aking up a hobby, painting the house and everyday chores: 
P10: So I start thinking …my brain then starts working overtime and
I start thinking about the things I really want to do…so it’s a real
turnaround. 
.4.5. Life-changing, a profound impact 
This theme represents a powerful response and impact following ke-
amine. One participant commented the difference was like ‘ day and
ight how I behaved, functioned and acted ’ (P6). All the participants, for
hom the treatment had an antidepressive effect, commented it was life
hanging: 
P13: It just, it, it had a knock-on effect with everything especially anxiety,
it was almost like a wonder drug for it to act so quickly, and to see
such huge change that I’d never seen before and haven’t really seen
since. 
The enormity or profoundness of the effect was apparent in the lan-
uage used: ‘ major impact…a drastic change ’ (P1), ‘discharged from mental
ealth team’ (P7), ‘ a profound effect’ (P8), ‘ketamine breathes life back into
e’ (P10), ‘erased… negativity’ (P12). 
.5. Treatment enhancers 
Participants identified environmental and psychological factors they
elt enhanced their treatment experience. Although a biological treat-
ent, ketamine is administered in a psychological and environmental
ontext. This theme is represented through three subthemes. 
.5.1. Conducive and safe environment 
The participants discussed how important the environment was for
nhancing their experience, several referring to feeling safe: ‘ I knew that
 was safe, I always felt safe’ (P6). Being able to relax facilitated a positive
etamine experience: ‘I was able to relax’ (P12). 
The patients described how the psychological environment aug-
ented their treatment experience: 
P9: It’s a very nice, nice environment as well, not clinical and that, that
really helps to put your mind at ease. 
.5.2. Medical expertise and professionalism 
This theme reflects how participants trusted the medical staff to ad-
inister procedures safely and support any medical needs during treat-
ent. This reduced anxiety, improving the experience: 
P11: Cannula in your hand, you know I was a bit anxious about that,
but they did it so well really didn’t feel much, and then, the doctors,
you know, just very efficient and doing their job. 
Many of the participants felt staff were very professional in the way
hey interacted: 
P9: …very professional so she was supporting and looking at my notesand checking the doses. 





































































































p  .5.3. Therapeutic alliance with caring staff
Across all narratives the therapeutic alliance formed with the staff,
ho participants felt were caring and compassionate towards them, was
 strong enhancer of treatment experience. Staff were described as: ‘ car-
ng ’ (P2), ‘ lovely, they really looked after us ’ (P4), ‘ so friendly and reassuring’
P6) and ‘ really kind’ (P9). The feeling was that each patient was treated
s an individual and staff connected effectively: 
P2: They are very, very caring they speak, they talk to you with your first
name, they treat you as an individual they read your notes, but they
also remember you and care for you and they connect with you . 
The participants emphasised the value of psychological support
hrough informal therapeutic input: 
P1: Talking with the nurses in the breakfast room is a huge benefit. …they
are so nice and easy to talk to, although it is a clinical procedure, it
doesn’t feel clinical….I would say it’s almost 50% the benefit you get
is that. 
.6. Barriers to treatment efficacy and success 
Some participants experienced barriers to treatment efficacy. For a
inority, they did not respond to the ketamine infusions, others finding
he effects lacked longevity. This theme is represented by 3 subthemes.
.6.1. Being a non-responder to ketamine 
Three participants reported no antidepressive effects: 
P9: I was not a responder after three treatments and I think that was,
that was sort of clear after one to be honest in terms of my reaction. 
When asked if he felt the treatment impacted on factors such as
ood, ability to think, engaging socially, sleep, and ability to cope, he
esponded: ‘ no effect on any of these whatsoever’ (P4). 
.6.2. Loss of ketamine effects over time 
The patterns of treatment effect longevity differed, some experienc-
ng longer-term benefits, while for others benefits were sustained over
 few days only: 
P11: Mood-wise, it does elevate me. Say I was having [treatment] on
Friday… my mood is fine and good. But by Monday, it’s gone. 
Having to manage and live with this cyclical pattern: 
P8: …you are climbing a mountain and you get to the top and then you
fall down the hill again. And you are back to square one and you,
look forward to Fridays again [another infusion] just to feel that a
lot, feel a lot different than you normally do. 
.6.3. Negative external and environmental factors 
Participants reported that if they experienced negative external fac-
ors, this could affect treatment experience and act as a barrier to treat-
ent success: 
P3: I had a young girl with me in the room, she was having treatment. It
was her first time of having ketamine and she freaked…. Screaming
like a banshee. And I just, it sent me on one…. I was screaming ‘just
get me out of this room’ …that week, ketamine had no effect on me
whatsoever. 
Other external factors impacted on treatment effect, for example:
eath in the family, events such as Christmas, unfamiliar and inexperi-
nced staff, or just having a bad day: 
P1: There is always the risk if you are having a bad day on the treatment
day, and this happened to me… I found that if I felt very negativelyon the treatment day, the effect actually doesn’t last as well. t  
6 .7. Advocate for treatment 
All participants recommended that others should try and have access
o the treatment, regardless of whether the treatment was effective or
ot for them. 
P11: It really works; I would recommend it…without a shadow of a
doubt… to anyone with long term, severe depression who’s tried lots
of other options. 
The advocacy was linked to the high quality of service provision: 
P2: I tell everyone wherever we go, whoever asked about such things I
just can’t stop talking about this place. What they provide here, it’s a
goldmine…it is getting the word out about this place. 
. Discussion 
For the majority of participants a consistent story emerges. Ketamine
nfusion causes some initial ‘high’, enhanced perception, and dissocia-
ion experience, followed by a lifting of mood, a reduction in or removal
f suicidal ideation and depression, improved ability to concentrate and
leep, lasting from around 3 to 6 days; these factors lead to an increase
n motivation, socialisation, and activity. People on maintenance ke-
amine are in a cycle of reduced or no depression symptoms (a return
o ‘normal’) and then a decline over a period of 5-7 days until their next
etamine infusion. Some participants were able to use ketamine to ex-
erience longer remission and return to a socially engaged, active and
urposeful life. Some participants report ketamine has a profound effect
nd is transformational; however, for others ketamine does not have an
ntidepressive effect, while others experience adverse effects preventing
hem from further treatment. All participants valued the therapeutic al-
iance with the clinic’s staff which enhanced the treatment experience,
nd all advocated ketamine treatment access for those who had not re-
ponded to other forms of antidepressant treatment. 
This study’s results add to other interview analysis results that
etamine causes an initial ‘high’, enhanced perception, and dissocia-
ion experience ( van Schalkwyk et al., 2018 ; Lascelles et al., 2019 ;
hillips et al., 2019 ). Most people tolerate adverse effects, and these
ffects may reduce over a course of treatment ( Sakurai et al., 2020 ),
eople engage in a risk/benefit analysis and most choose to have ke-
amine ( Fairchild et al., 2020 ). As has been found in other studies, the
ntidepressive effect is rapid, trails off, and longevity of effect varies
etween individuals ( Sakurai et al., 2020 ). Neurocognitive function
mprovement, reduction or removal of suicidal ideation and depres-
ion symptoms, elevated mood, and improved functioning and socia-
ility are all patient-reported beneficial effects ( van Schalkwyk et al.,
018 ; Jilka et al., 2019 ; Lascelles et al., 2019 ; Phillips et al., 2019 ;
hiroma et al., 2020 ). 
Ketamine is a biological treatment; however, the holistic view
f treatment delivery is that psychological (mind) and biological
brain) interventions interact to affect outcomes and treatment efficacy
 Rosendale, 2009 ). Ketamine is administered within a psychological and
nvironmental context, in this study the treatment environment was per-
eived as safe and relaxing: one that augmented, enriched, and enabled
 positive treatment experience. The therapeutic alliance between pa-
ients and staff was also identified as a contributory factor for enhanc-
ng treatment experience. This is in line with research which suggests
 positive relationship between the therapeutic alliance and outcomes
 Flückiger et al., 2018 ). 
Study limitations include the small sample size, the potential lack
f generalisability associated with the qualitative methodology, people
ho agreed to participate were self-selected and there may be some bias
n terms of those agreeing to participate having a more positive experi-
nce and to be currently experiencing fewer depression symptoms. The
articipant group is quite small at 13 but a good number for a quali-
ative in-depth interview study as saturation often occurs at around 12
















































































































R  articipants in relatively homogeneous groups ( Guest et al., 2006 ). Al-
hough some participants had additional diagnosis to TRD, it is quite
ften the case in a TRD population. The participants all attended a sin-
le clinic and all identified as ‘White British’ reducing generalisability.
lthough, we only recruited patients from one ketamine clinic for de-
ression, there are only two in the UK so this clinic represents 50% of
he UKs service provision and it draws patients from a national popula-
ion. The interviews were conducted retrospectively and at varying time
eriods following initiation of treatment. 
In conclusion, ketamine has risks, adverse side effects, and, for some,
s not tolerated and does not have antidepressive effects. It has benefi-
ial effects for others and life transforming for some. It is imporatnt to
ave a treatment environment where patients feel supported, safe and
elaxed to maximise the chance of a positive and mimimise chance of a
egative expereince. There is some evidence of sustained antidepressant
ffects with once-weekly maintenance treatment ( Phillips et al., 2019 ).
eople with TRD continue with maintenance ketamine treatment due
o perceived significant improvement ( Sakurai et al., 2020 ). Ketamine
ay be a source of hope for patients for whom other treatments have
ot been effective ( Krystal et al., 2019 ). People who experience depres-
ion have expressed hope for acceptance of ketamine as a drug that
mproves people’s lives, reduces symptoms of depression and improves
unctioning ( Jilka et al., 2019 ). This present study adds value in provid-
ng a first-hand patient perspective of ketamine for depression. Further
esearch could investigate if people who received ketamine developed
abitational effects, while positive and negative effects of ketamine de-
lined or increased, and if doses needed to be subsequently escalated.
arger sample surveys of ketamine experience and further exploration
f topics raised with qualitative methods such as in-depth interviews are
arranted. 
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